MIRA Pharmaceuticals, Inc. (MIRA) Stock

MIRA Pharmaceuticals, Inc. (MIRA) is a Healthcare stock trading at $0.96 (as of 2026-06-18), with a market capitalization of $51.10M and a trailing P/E of -0.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

MIRA Pharmaceuticals, Inc. is a clinical development-stage biopharmaceutical company focused on developing a synthetic THC analog. Its program includes MIRA1a, a cannabinoid receptor-targeting compound intended for treatment of adult patients with anxiety and cognitive decline associated with early-stage dementia, as well as chronic pain.

Valuation — source: SEC EDGAR (first-party)
Price$0.96
Market Cap$51.10M
P/E Ratio-0.7
Price / Book4.28
DCF Value (model)$-1.74
DCF Upside vs Price-280.8%
Profitability & Growth — source: SEC EDGAR
Return on Equity-104.9%
Current Ratio82.16
Valuation vs Sector & Industry
Stock P/E-0.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-103.6%
vs Industry-104.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($997350.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOErez Aminov
Employees2
CountryUS
IPO Date2023-08-14

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • PMV Pharmaceuticals, Inc. (PMVP)
  • MediciNova, Inc. (MNOV)
  • Voyager Acquisition Corp. (VACH)
  • Clene Inc. (CLNN)
  • ALX Oncology Holdings Inc. (ALXO)
  • Metagenomi, Inc. Common Stock (MGX)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • MAIA Biotechnology, Inc. (MAIA)
MIRA earnings history · MIRA institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.